

Review Article

New Strategy of Micronutrients Combined with Dietary and Lifestyle Adjustment for Alzheimer's Disease Therapy and Partially Restoration

Guanghai Xiu³; Yueqin Zeng^{2*}; Jin-Tao Li^{1*}¹The Institute of Neuroscience of Kunming Medical University, China²School of Biomedical Engineer, Kunming Medical University, Kunming, Yunnan, China³Department of Intensive Care Unit, the Affiliated Hospital of Yunnan University (the Second People's Hospital of Yunnan Province), Yunnan University, Kunming, Yunnan Province, China***Corresponding author: Jin-Tao Li**

No 1168 of Chun Rong West Road, the Institute of Neuroscience of Kunming Medical University, 650500, China

Yueqin Zeng

School of Biomedical Engineer, Kunming Medical University, Kunming, Yunnan, 650500 China.

Email: kmljintao@163.com; z_yueqin@hotmail.com

Received: June 28, 2023**Accepted:** July 28, 2023**Published:** August 04, 2023

Introduction

Alzheimer's disease (AD), known as one of the most common cause of dementia, is characterized by the senile plaque and Neurofibrillary Tangles (NFTs) mainly formed and deposited in the hippocampal area of AD patients. Individuals, who are 65 years or older, have higher and higher risk of developing this neurodegenerative disease due to the coming of aging society worldwide. Progressive cognitive, learning and memory disorders occur and become the most distinctive manifestation in this disease, accompanied with other neurological and/or mental symptom, such as weakness, depression, etc. Until now, it is still a challenge that seems to unable to overcome to effectively reduce the incidence or the rate of progression of AD, with few curative therapeutic strategies. Even so, several pathological reactions that contribute to degeneration and death of neurons in AD have been identified in last few decades, including such factors as increased oxidative stress, chronic inflammation, A β 1-42 peptides generated from the cleavage of Amyloid Precursor Protein (APP), high cholesterol levels, etc., which are currently attracted more and more attention and becoming the main target factors focused on both in experimental research and clinical trials.

Abstract

Alzheimer's Disease (AD) is the leading cause of dementia resulting in memory loss, difficulty with thinking, and behavioral changes. To date, AD is continuously known as an incurative disease of the aged, and therefore has been widely considered as a challenge for clinical neurology both in the therapy, prevention and prognosis as well, thus bringing about heavy burden to not only the patients, their family, but also even the society. In this review, it has been proposed a new strategy synthetically implemented for the prevention and even partially restoration of Alzheimer's Disease (AD), in which multiple micronutrients, combined with diet and lifestyle adjustment, were used for AD patients and people who already had the pro-phase symptom. Based on the notions, evidence and beneficial methods are put forward. It is promising to install a better and more efficacious AD administration system, with aim to reduce the incidence rate and elevate the life quality of AD patients in a sooner future.

Keywords: Combining therapeutic strategies; Micronutrients; Lifestyle adjustment; Alzheimer's disease; Therapy and restoration

Despite these advances in our understanding of AD, no evidence-based strategy has been proposed to reduce the risk of AD or to improve the efficacy of drug therapy in the management of AD. Current drug therapies are mainly based on the symptoms rather than on the causes of the disease. For example, acetylcholinesterase inhibitors and an antagonist of glutamate receptor N-methyl-D-Aspartate (NMDA) are used to attenuate the symptoms of dementia and relieve the anxiety and fear associated with AD, respectively. They can exert modest beneficial effects on attenuating these symptoms, but with unpleasant side effects. Of note, they did not effect on increased oxidative stress or chronic inflammation which plays a key role in the development and progression of AD.

It has been found in recent years that the antioxidant strategy, when combining with standard therapy, could improve the management of this disease more than that produced by standard therapy alone. This proposed and preliminarily used novel therapeutic strategy is mainly based on Antioxidants that are long proved to have the ability to neutralize free radicals and reduce chronic inflammation. Therefore, it is indispensable to

develop antioxidant-based therapeutic strategies and simultaneously reduce the risk of AD in high-risk populations, such as older individuals and individuals with a family history of AD levels for significant elevation of more intensive and precise disease administration of AD.

In recent years, some reports indicated that a micronutrient preparation containing dietary and endogenous antioxidants, vitamin D, B-vitamins, and certain minerals played roles in reducing the risk of AD and resisting the unfavorably factors that raising along with age, such as chronic oxidative stress [1]. However, there are few research and outcome reported involving the effects of micronutrient combining with antioxidants, and other beneficial methods on the amelioration of AD prevention, treatment and prognosis. It is needed systematic research in a larger population with multi-center studies, and for a long term follow-up and elaborate survey. Apart from these, the pathogenesis of AD still awaits further elucidation.

Therefore, it is an indispensable strategy to get AD relieved not only in its incidence rate, but also increase the therapeutic effects and the life quality by the help of effective methods with which to reduce the level of oxidative stress all along during all the course of AD. It seems that micronutrient combining with antioxidants, and other beneficial method is promising on the amelioration of AD treatment and prognosis as well, which are deserved to be widely and intensively studied.

Current Treatments of AD

Current treatments of AD are totally unsatisfactory, because they are based on the symptoms rather than on the causes of the disease. These treatments have failed to stop the progression of the AD. Commonly prescribed drugs are cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and NMDA antagonist (memantine). The purpose of cholinesterase inhibitors is to improve cognitive function by increasing the acetylcholine levels in cholinergic neurons. The efficacy of these drugs depends upon the viability of surviving cholinergic neuron. The purpose of NMDA receptor antagonist is to stop the action of glutamate which induces fear and anxiety in patients with AD. In randomized, double-blind, parallel-group clinical trials, all Acetylcholinesterase Inhibitors (AChEIs) have shown varying degrees of efficacy than placebo in improving cognitive function in patients with mild to moderate AD. Among donepezil, galantamine, and rivastigmine, donepezil was found to be slightly more effective than others, [2] but others have reported no such difference between these drugs (Birks J, *et al.*, 2006). In the Hispanic population, the safety and beneficial effects of donepezil on cognitive function were similar to those found in the general population [3]. The annual cost of donepezil, galantamine, and rivastigmine was not significantly different [4]. These drugs do not affect the level of oxidative stress or chronic inflammation primarily responsible for neurodegeneration in AD brain; therefore, their efficacy does not last for a long period of time. The progression of the disease continues to occur because of oxidative stress- and chronic inflammation-induced progressive neuronal death. The addition of agents that can reduce oxidative stress and chronic inflammation to the current therapeutic modalities may prolong the effectiveness of AChEI in improving cognitive function in AD patients. Therefore, we propose that antioxidants that neutralize free radicals and reduce inflammation and a NSAID that reduces inflammation should be utilized in combination with standard therapy in order to improve the current management of AD.

Statins are commonly used in the prevention and treatment of heart disease. However, the outcomes achieved, such as reducing senile plaques and inflammation marker TNF-alpha by using atorvastatin and pitavastatin were only obtained from the AD transgenic mice [5], without verification in human AD. Another agents seems useful to AD were known as neurotrophic molecule J147. It has been found that it could significantly improve cognitive function even when administered at a late stage of the disease [6]. The effects of J147 was found mediated by inducing Nerve Growth Factor (NGF) and several Brain-Derived Neurotrophic Factor (BDNF)-responsive proteins which are considered important for learning and memory. But this outcome was just limited in AD mice model, either.

Limitations of Current Medications in AD

It has been proposed that the gradual loss of cognitive functions in AD is due to the loss of cholinergic neurons; therefore, cholinergic drugs (acetylcholinesterase inhibitors) are used to improve the function of surviving neurons in AD patients. However, these agents do not protect cholinergic neurons against the damaging effects of oxidative and nitrosylative stresses and chronic inflammation. Consequently, neurons continue to die, and the beneficial effects of cholinergic drugs do not last long.

Recommended Micronutrients and Low Dose of nsaid in Combination with Standard Therapy in Patients with Dementia with or without AD

Nowadays, acetylcholinesterase inhibitors are commonly utilized clinically to improve cognitive function by enhancing the activity of surviving cholinergic neurons in AD patients. However, these drugs only improved cognitive function by enhancing the activity of surviving cholinergic neurons in AD patients, whereas do not protect cholinergic neurons against the damaging effects of oxidative and nitrosylative stresses and chronic inflammation. Consequently, neurons continue to die despite this treatment, and thus, beneficial effects of cholinergic drugs last as long as neurons are alive. A supplement with an antagonist of glutamate receptor NMDA can be useful in reducing anxiety and fear in AD patients. This drug does not affect oxidative stress or chronic inflammation.

Antioxidants are well known to reduce oxidative stress, chronic inflammation, and release and toxicity of glutamate. And Aspirin can enhance anti-inflammation effects of antioxidants. Therefore, addition of a multiple micronutrient preparation and a low-dose aspirin in combination with standard therapy may prolong the beneficial effects of current drugs in patients with dementia with or without AD by protecting surviving neurons from damage produced by increased oxidative stress, chronic inflammation, and glutamate. The proposed combination of micronutrients recommended for primary prevention is applicable to those who are at the various stages of AD and taking medications. The daily doses are divided into two doses (half in the morning and half in the evening preferably with meal) and are administered orally (Table 1).

Table 1: The useful supplementary multiple micronutrient and dietary strategy for AD prevention.

Nutraceuticals Food supplements	
Bioactive substances	Vitamins, salts, amino acids, plant extracts
Supplied as pharmaceutical preparations	Supplied by diet
Prevention or treatment of diseases	Compensation for food shortage




Figure 1: Appropriate exercise reduces the incidence rate or postpones the occurrence of AD.

In most studies, the serum levels of vitamin B12 in AD patients were significantly lower than in controls, and this may in part contribute to degeneration of neurons [7,8]. Indeed, vitamin B12 supplementation increased cholineacetyltransferase activity in cholinergic neurons of cats [9] and improved cognitive functions in AD patients [10]. An analysis of published data revealed that there was no adequate benefit from folic acid supplementation with or without vitamin B12 on cognitive function or mood of healthy elderly people [11]. So, Appropriate Vitmaine B12 supplementation can increase the activity of cholineacetyltransferase, thus would do good to the improvement of cognitive functions of AD patients.

Diet and Lifestyle Recommendations for AD

Even though there is no direct link between the diet- and lifestyle-related factors and the initiation or progression of AD, it would be beneficial to avoid exposure to aluminum and excessive consumption of iron, copper, manganese, or zinc. It is always useful to include a balanced diet that contains low fat and high fiber with plenty of fruits and vegetables. Among fruits, blueberries and raspberries are particularly important because of their protective role against oxidative injuries in brain. Lifestyle recommendations include daily moderate exercise, reduced stress, no tobacco smoking, and reduced exposure to noise and electromagnetic fields. Diet- and lifestyle-related recommendations (Figure 1) can be adopted together with the proposed micronutrients for primary prevention, secondary prevention, and treatment strategies.

Discussions

The results of many studies presented in this chapter suggest that increased oxidative stress is one of the earliest biochemical events which initiate neurodegeneration in AD. Other biochemical defects, such as mitochondrial dysfunction, increased levels of chronic inflammation, generation of A β 1-42 peptides from APP, aggregation of A β peptides, hyperphosphorylation and acetylation of tau, inhibition of proteasome, and formation of extracellular senile plaques and intracellular NFT occur subsequent to increased oxidative stress. In addition, mutation in APP, presenilin-1, and presenilin-2 genes increased the generation of A β peptides which damage neurons by producing more free radicals. Increased oxidative stress together with other biochemical and genetic defects participate in the progression and final stage of neuronal death in AD. At present, there are no effective strategies to reduce the incidence of AD.

It is proposed that a combination of agents which can increase antioxidant enzymes by activating Nrf2/ARE pathway without ROS stimulation and which can directly scavenge free radicals may be necessary to reduce oxidative stress and

chronic inflammation optimally in AD. Dietary and endogenous antioxidants, curcumin, resveratrol, and omega-3 fatty acids can fulfill the above requirements for reducing oxidative stress and chronic inflammation optimally. Thus, a preparation of the above antioxidants in combination with low dose NSAIDs, such as aspirin, may be useful in reducing chronic inflammation optimally. As we summarized in this review, clinical studies using the proposed micronutrient recommendations for primary and secondary prevention should be initiated.

The current drug treatments are based on the symptoms rather than the causes of AD and has produced transient benefits on some symptoms such as improving cognitive function; however, these drugs do not have any effect on increased oxidative stress and chronic inflammation that are responsible for neuronal degeneration. The effectiveness of cholinesterase inhibitors in improving cognitive function lasts as long as cholinergic neurons are viable. Excessive release of glutamate may induce fear and anxiety in AD patients. Glutamate is also toxic to nerve cells. Therefore, memantine, an antagonist of glutamate receptor NMDA, is used to improve these symptoms of AD. The currently used drugs have severe side effects. The micronutrient strategies recommended for primary prevention can also be used in combination with standard medications to improve the management of AD by reducing the progression of the disease and prolonging the efficacy of drugs on the symptoms.

Dietary recommendations include low-fat and high-fiber diet and reduced consumption of iron, copper, and zinc. Lifestyle recommendations include stopping tobacco smoking and reducing exposure to noise and electromagnetic fields.

Taken together, it has been proposed that micronutrient with a NSAID recommendations in combination with standard therapy for improved management of AD should be initiated. And combined with dietary and lifestyle adjustment are effective in prevention or improved management of AD likewise a novel, simple and more effectively auxiliary strategy both for prevention and treatment of AD, which is worth studying on a large scale.

Author Statements

Acknowledgement

This work has been greatly supported by the 2018ZF002/Yunnan Biopharmaceutical Major Project, China and the 202001AY070001-166/Yunnan Provincial Department of Science and Technology - Kunming Medical University Joint Special Fund.

Author's Contributions

Jintao Li is responsible for all the aspects of this review, including design, writing and the notions of this review.

Guanghai Xiu and Yueqin Zeng are the idea, notion and designer and provides the valuable materials for the review.

Ethics Approval and Consent to Participate

All the notions of this review are accordant with the principle of the Animal Ethics of KMMU, Kunming, Yunnan Province, China.

Consent for Publication

I agree with the policies for publication of the journal of "Aging Pathology and Therapeutics".

References

1. Prasad KN, Cole WC, Prasad KC. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. *J Am Coll Nutr.* 2002; 21: 506-22.
2. López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. *Dem Geriatr Cogn Disord.* 2005; 19: 189-95.
3. Lopez OL, Mackell JA, Sun Y, Kassalow LM, Xu Y, McRae T, et al. Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study. *J Natl Med Assoc.* 2008; 100: 1350-8.
4. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. *J Manag Care Pharm.* 2008; 14: 451-61.
5. Kurata T, Miyazaki K, Morimoto N, Kawai H, Ohta Y, Ikeda Y, et al. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. *Neurol Res.* 2013; 35: 193-205.
6. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. *Alzheimers Res Ther.* 2013; 5: 25.
7. Mrak RE, Griffinbc WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. *Neurobiol Aging.* 2001; 22: 915-22.
8. Paradisi S, Sacchetti B, Balduzzi M, Gaudi S, Malchiodi-Albedi F. Astrocyte modulation of in vitro beta-amyloid neurotoxicity. *Glia.* 2004; 46: 252-60.
9. Thal DR. The role of astrocytes in amyloid β -protein toxicity and clearance. *Exp Neurol.* 2012; 236: 1-5.
10. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. *Int J Biochem Cell Biol.* 2005; 37: 289-305.
11. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. *Neurology.* 2009; 73: 768-74.